In summary, our results highlight the efficacy of MNK inhibitors to increase CD8+ T cell infiltration and to enhance the antitumor effects of anti–PD-1 antibody in mouse models of pancreatic and differentiated thyroid cancer. Here, CD8A is linked to thyroid cancer.